A recent study conducted by nference, a Massachusetts-based firm, analyzed data from approximately 8,000 patients to compare the effects of weight loss drugs tirzepatide (Mounjaro) and semaglutide (Ozempic). The findings revealed that patients using tirzepatide lost about 1.1% more lean body mass after three months, with the difference increasing to 2% after 12 months. This is significant as lean body mass, which includes muscle and connective tissue, is crucial for maintaining strength and metabolism. Experts caution that while weight loss is often viewed positively, excessive muscle loss can lead to reduced physical performance and increased injury risk. The study also highlighted that higher doses, longer treatment durations, and pre-existing musculoskeletal conditions can increase the risk of losing lean body mass. Additionally, reduced exercise tolerance was linked to greater muscle loss, particularly in those taking tirzepatide. The study underscores the importance of combining medical treatment with regular exercise and proper nutrition to ensure sustainable weight loss while preserving muscle health.